Mona K. Tawfik

Prof. Dr. Mona K. Tawfik


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
EMEman Mehanna
Eman Mehanna
BBBassant Barakat
Bassant Barakat
MEMohamed H. ElSayed
Mohamed H. ElSayed
MTMona K. Tawfik
Mona K. Tawfik



1 August 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MTMona K. Tawfik
Mona K. Tawfik
MMMagda I. Mohamed
Magda I. Mohamed

13 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MEMohamed El-Sherbiny
Mohamed El-Sherbiny
RERehab m. El-Sayed
Rehab m. El-Sayed
MHMohamed A. Helal
Mohamed A. Helal
AIAfaf T. Ibrahiem
Afaf T. Ibrahiem
HEHoda S. Elmahdi
Hoda S. Elmahdi
SZSawsan Zaitone
Sawsan Zaitone
Nifuroxazide is an antidiarrheal medication that has promising anticancer activity against diverse types of tumors. The present study tested the anticancer activity of nifuroxazide against Ehrlich’s mammary carcinoma grown in vivo. Furthermore, we investigated the effect of nifuroxazide on IL-6/jak2/STAT3 signaling and the possible impact on tumor angiogenesis. The biological study was supported by molecular docking and bioinformatic predictions for the possible effect of nifuroxazide on this signaling pathway. Female albino mice were injected with Ehrlich carcinoma cells to produce Ehrlich’s solid tumors (ESTs). The experimental groups were as follows: EST control, EST + nifuroxazide (5 mg/kg), and EST + nifuroxazide (10 mg/kg). Nifuroxazide was found to reduce tumor masses (730.83 ± 73.19 and 381.42 ± 109.69 mg vs. 1099.5 ± 310.83) and lessen tumor pathologies. Furthermore, nifuroxazide downregulated IL-6, TNF-α, NFk-β, angiostatin, and Jak2 proteins, and it also reduced tumoral VEGF, as indicated by ELISA and immunohistochemical analysis. Furthermore, nifuroxazide dose-dependently downregulated STAT3 phosphorylation (60% and 30% reductions, respectively). Collectively, the current experiment shed light on the antitumor activity of nifuroxazide against mammary solid carcinoma grown in vivo. The antitumor activity was at least partly mediated by inhibition of IL-6/Jak2/STAT3 signaling that affected angiogenesis (low VEGF and high angiostatin) in the EST. Therefore, nifuroxazide might be a promising antitumor medication if appropriate human studies will be conducted.